Among the factors which predispose to and modulate rheumatoid arthritis, sex hormones are important: androgens act as natural immunosuppressants and oestrogens perhaps as enhancers of the immune response.' Low androgen concentrations are present before and after the onset of rheumatoid arthritis in both male and female patients. 2 In particular, serum levels of the adrenal androgen, dehydroepiandrosterone (DHEA) sulphate, are found to be consistently low, while an inverse correlation with disease severity has been shown.' ' Some in vitro studies support the view that androgens may be regarded as natural immune suppressors: they inhibit the production of cytokines by activated murine T lymphocytes' and they increase suppressor cell activity in both thymocytes and lymphocytes. Furthermore, human macrophages carry functional cytoplasmic and nuclear androgen receptors6; these macrophages are abundant in synovial tissue from patients with rheumatoid arthritis. Androgen receptors have also been observed on cultured human fetal chondrocytes. In animal models of rheumatoid arthritis, testosterone was found to reduce inflammation and inhibit the occurrence of erosions. 7 There are only limited data on the possible clinical effects of androgen treatnent for patients with active rheumatoid arthritis. What was probably the first study was published in 1950. 8 Testosterone propionate was given to a limited number ofpatients with active rheumatoid arthritis and it was concluded that significant improvement, or even remission, might follow treatment of early rheumatoid arthritis. However, side effects limited the feasibility of this approach. In The Netherlands the beneficial effect of testosterone propionate in a female rheumatoid arthritis patient was observed by a general practitioner (Booij A Sr, unpublished clinical observation, 1960. In a more recent study, treatment of postmenopausal rheumatoid arthritis patients with 19nortestosterone for six months was found to improve chronic anaemia but not indices of disease activity or functional capacity.9 In a study of male patients the effect of (oral) testosterone undecanoate on rheumatoid arthritis disease activity was more evident'0: erythrocyte sedimentation rate (ESR) and IgM rheumatoid factor levels decreased, as did the number of tender joints and the daily intake of non-steroidal anti-inflammatory drugs (NSAID).
On the grounds of these in vitro and in vivo findings we performed a double blind, placebo controlled study of postmenopausal women with rheumatoid arthritis to determine the effects of testosterone on disease activity. According to this definition, at 12 months 12 patients of the testosterone group (21%) and only two in the placebo group (4%) fulfilled these criteria (P < 0.01). Since there was a significant difference in two indices of disease activity between the two groups at the start of the study, change scores were calculated (table  3) . There was significantly more improvement after one year in pain score (4 v 1; 95% confidence intervals (CI) -1 to 7 v -3 to 4), ESR (9 v 0; 95% CI 4 to 14 v -3 to 3), and disability score (0.24 v -0.24; 95% CI -0.01 to 0.46 v -0.49 to 0.03) in the testosterone group.
Methods
Monitoring of safety indices at one year showed a significant increase in haemoglobin concentration in the testosterone group (0.3 mmol litre-') v no change in the placebo group.
No changes were found for the serum levels of creatinine, alkaline phosphate, or y-glutamyl transferase (data not shown).
Patients were asked whether or not they would like to continue their allocated medication after completing one year of treatment: 67% of the testosterone group wanted to continue treatment versus only 37% of the placebo group; this is a statistically significant difference.
As an additional index, the number of joints injected with corticosteroids was recorded. Ten patients of the testosterone group received a total of 14 injections; in the placebo group nine patients received a total of 18 injections: the difference is not significant. No significant change in the use of NSAID was found between the two groups during treatment.
Only 68 patients completed one year of treatment: 36 of 57 patients in the treatment group and 32 of 50 patients in the placebo group. No difference was found in demographic or disease characteristics between the total group (n = 107), those who completed this study (n = 68), and those who dropped out (n = 39; data not shown).
The most important reasons for dropping out were (table 4): protocol violation (n = 5; testosterone 3; placebo 2), side effects (n = 6; testosterone 2; placebo 4), and lack of efficacy (n = 28; testosterone 16; placebo 12; 18 in the first period). Every change in disease modifying antirheumatic drug dose was considered a lack of efficacy.
Protocol violations occurred when the patient's own general practitioner or local rheumatologist objected to this adjuvant therapy (three patients), one patient moved to southern Europe, and one patient went into remission. Six patients stopped treatment because of side effects: two suffered palpitations and general malaise (1 testosterone and 1 placebo), one reported loss of hair (placebo), and one had gastrointestinal symptoms (testosterone). One woman died of a myocardial infarct (placebo) and one had a thrombosis of the central retinal vein (placebo).
The most common side effects are listed in It is relevant to note that adjuvant treatment with oestrogens of postmenopausal women also led to an improvement in general wellbeing (and bone mass) but had no effect on disease activity.19 20 Adjuvant treatment with androgens might cause more immunomodulation in rheumatoid arthritis than adjuvant treatment with oestrogens. Treatment with testosterone of postmenopausal women with rheumatoid arthritis is likely to improve bone mass2; however, this was not assessed in this study.
In conclusion, we suggest that androgens can be considered as adjuvant therapy for postmenopausal women with rheumatoid arthritis: theoretically the effect is anabolic and perhaps also slightly disease modifying. Since more potent disease modifying agents are available, the main indication for androgen treatment will probably be improvement of the catabolic state prevalent among so many of the elderly patients with active rheumatoid arthritis. 
